Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)

Overview

About this study

The purpose of this study is to establish an international secure, web-based clinical database andrepository of aPL-positive patients that the natural course of at least 2000 patients can be followed over 10 years.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18-75.
  • Persistent (at least 12 weeks apart) aPL-positivity within 12 months prior to the screening defined as: o aCL IgG/M/A (> 40U, medium-to-high titer, and/or greater than the 99th percentile) and/or o aβ2GPI IgG/M/A (>40U, medium-to-high titer, and/or greater than the 99th percentile) and/or o Positive LA test based on the International Society of Thrombosis & Haematosis Recommendations.

Exclusion Criteria:

  • Patient refusal.
  • Inability to comply with study and follow-up procedures.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ali Duarte Garcia, M.D.

Open for enrollment

Contact information:

Annie Streicher

(507) 422-9855

Streicher.Annie@mayo.edu

More information

Publications

Publications are currently not available